According to TipRanks, Benjamin is an analyst with an average return of -12.5% and a 29.67% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Incyte, Blueprint Medicines, and Spectrum Pharmaceuticals.
Currently, the analyst consensus on Inhibrx is a Strong Buy with an average price target of $44.33.
INBX market cap is currently $788.2M and has a P/E ratio of -7.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates.
Read More on INBX: